Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
Insights into implementation of sacubitril/valsartan into clinical practice - Martens - 2018 - ESC Heart Failure - Wiley Online Library
Kidney Research and Clinical Practice
Forest plot of indirect comparisons used to estimate the effects of... | Download Scientific Diagram
PDF) Estimating the Lifetime Benefits of Treatments for Heart Failure
Frontiers | Assessment of Ultra-Early Administration of Sacubitril Valsartan to Improve Cardiac Remodeling in Patients With Acute Myocardial Infarction Following Primary PCI: Rational and Design of a Prospective, Multicenter, Randomized Controlled Trial
JCM | Free Full-Text | Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF - ScienceDirect
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial - ScienceDirect
Sacubitril/Valsartan: Where are we now? | BCS
Practical guidance on the use of sacubitril/valsartan for heart failure | SpringerLink
Frontiers | Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/ valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY‐HF study -
Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study - eClinicalMedicine
Frontiers | Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
IJMS | Free Full-Text | Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
Sacubitril/Valsartan For Heart Failure & Ejection Fraction
Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan | NEJM
Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan | NEJM
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan | Scientific Reports
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial | JACC: Heart Failure
Sacubitril/Valsartan For Heart Failure & Ejection Fraction
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review - Rui Zhang, Xiaotong Sun, Ya Li, Wenzheng He, Hongguang Zhu, Baoshan Liu, Aiyuan Zhang, 2022
